BioTrinity Participants


BioTrinity is Europe's Leading BioPartnering and Investment Conference. It brings together investors, pharmaceutical executives and innovative life science R&D companies under one roof. How is this achieved? BioTrinity provides participants with access to each other via one-to-one meetings scheduled through the partnering system; at panel discussions where panelists address the tricky questions of the day and in turn, take questions from the audience; and at the exhibition and social events. The conference offers business activities for all participants that can only be achieved at BioTrinity. With an attendance in 2014 of 1,014 participants, including 130+ investor delegates, if you need to sell your products and services, your company or even yourself, BioTrinity offers you that forum as many of the BioTrinity participants come to the conference to network, partner and do business with other participants.

BioTrinity 2014 highlights

  • 1,014 delegates from 32 countries
  • 624 companies
  • 184 speakers
  • 107 company showcase presentations
  • 2,462 one-to-one meetings
  • 130+ investor delegates from 12 countries
  • 61 exhibitors
  • 80 global pharma/corporate venture delegates
  • 33 global pharma/medical technology corporates

Read the testimonials received from delegates from previous years to find out what other delegates say...

Companies who are attending BioTrinity 2015 to date:

Red = Global Pharma/MedTech Corporates
Green = Investment Firms

A  |  B  |  C  |  D  |  E  |  F  |  G  |  H  |  I  |  J  |  K  |  L  |  M  |  N  |  O  |  P  |  Q  |  R  |  S  |  T  |  U  |  V  |  W  |  X  |  Y  |  Z

 

  • AbbVie (United States)
  • Abbvie Deutschland GmbH & Co. KG (Germany)
  • ABHI (Association of British Healthcare Industries)
  • Abingworth LLP
  • Ablynx (Belgium)
  • Absynth Biologics Ltd
  • Abzena Plc
  • Advantage Austria (Austria)
  • Air Liquide
  • Alacrita LLP
  • Albion Technology & General VCT plc
  • Albion Ventures LLP
  • Amgen
  • Angel Capital Group (incorporating London Business Angels)
  • Aptus Clinical
  • Arthurian Life Sciences Ltd
  • Arthur J Gallagher
  • AstraZeneca (Sweden)
  • AstraZeneca
  • Atelix Ltd
  • Aurelia Bioscience
  • Autonomous University of Barcelona (Spain)
  • Bay City Capital (Switzerland)
  • Bench International
  • BioAscent Discovery Ltd
  • Biotechgate (Switzerland)
  • Biotech Personnel
  • Biotechpharma UAB (Lithuania)
  • Boehringer Ingelheim GmbH (Germany)
  • Bone Therapeutics (Belgium)
  • Bristol-Myers Squibb (United States)
  • British Heart Foundation
  • BTG International Inc (United States)
  • BTG International Ltd
  • Cambridge Enterprise
  • Cambridge Healthcare & Biotech
  • Cambridge Innovation Capital
  • Catalent (USA)
  • Cell Medica Ltd
  • Chronos Therapeutics Ltd
  • CibaGen Ltd
  • Citigate Dewe Rogerson
  • Cloud Pharmaceuticals Inc (United States)
  • Colpman Consulting Ltd
  • Context Design Ltd
  • Covington & Burling LLP
  • Coulter Partners
  • Current Partnering
  • Cytox Ltd
  • data magik ltd
  • Delta Partners (Ireland)
  • Diamond BioPharm Ltd
  • Domainex Ltd
  • Dora Wirth Languages Ltd
  • Dundee City Council
  • Durbin
  • EBD Group (Germany)
  • Edmond de Rothschild Investment Partners (France)
  • Eli Lilly and Company
  • Epidarex Capital
  • EY
  • ex scientia
  • Exonate Ltd
  • Ferrer Internacional SA (Spain)
  • Fidelity Biosciences
  • Fieldfisher
  • Finance Wales
  • Forbion (Netherlands)
  • Fountain Healthcare Partners (Ireland)
  • F-star Biotechnology Ltd
  • Gentronix Ltd
  • george james ltd
  • GHO Capital Partners LLP
  • GlobalData
  • Gilde Healthcare (Netherlands)
  • Hill Street Holdings
  • Horton Ruston Poole
  • IFR BioMed
  • Imanova Limited
  • Imperial Innovations
  • Index Ventures
  • Innovate UK
  • Instinctif Partners
  • Intelligent Ultrasound
  • Interea International
  • IP Group plc
  • IPI (Austria)
  • Irving Levin Associates Inc (USA)
  • Isis Innovation Limited
  • J A Kemp
  • James Cowper LLP
  • J&J Innovation
  • King's College London
  • Kurma Partners (France)
  • Life Science Nation (USA)
  • LSP (Netherlands)
  • Lundbeckfond Ventures (Denmark)
  • Magnomics (Portugal)
  • MedNous
  • Mercia Fund Management
  • MGB Biopharma Ltd
  • MICROBIAL SOLUTIONS LTD
  • Midven
  • MiNA Therapeutics
  • Mitsui & Co Global Investment (United States)
  • Molplex Pharmaceuticals
  • Momentum Bioscience
  • MS Ventures (Netherlands)
  • MS Ventures (Switzerland)
  • Nanomerics Ltd
  • NeoMed (Switzerland)
  • New Hill Management
  • NIHR Clinical Research Network
  • Norgine Ventures
  • Novo A/S (Denmark)
  • Novo Nordisk (Denmark)
  • O2h Ventures
  • Osborne Clarke
  • Oxford AHSN
  • Odgers Berndtson
  • Oxford Cancer Biomarkers Ltd
  • Oxford Capital
  • Oxford Technology
  • OxSonics Ltd
  • Oxtex
  • Pennington Manches LLP
  • PGXIS
  • Pharmalicensing
  • pharmaphorum
  • Pharmaterials Ltd
  • Philips
  • Piramal Healthcare
  • PRECLIN Biosystems AG (Switzerland)
  • Premier Research
  • Prokarium
  • Proximagen Ltd (UK)
  • PsiOxus Therapeutics Ltd
  • QED Life Sciences
  • QRC Consultants Ltd
  • Quanta Fluid Solutions
  • Queen Mary University of London
  • Re-Pharm
  • RedHill Biopharma (Israel)
  • Richardsons Chartered Accountants
  • RRG, a VCLS Company
  • Safeguard Biosystems
  • Sareum
  • Selcia Ltd
  • Seroba Kernel (Ireland)
  • Seventure Partners (France)
  • Shire Pharmaceutical
  • Sigma Aldrich
  • Silicon Valley Bank
  • Sitatunga Ltd
  • Sofinnova (Italy)
  • SPARK Impact
  • SR One
  • SV Life Sciences
  • Swiss Biotech Association (Switzerland)
  • Sygnature Discovery Ltd
  • Synairgen Research Ltd
  • Takeda Pharmaceuticals International Inc (USA)
  • Takeda Ventures Inc (United States)
  • Talentmark
  • Teijin Pharma Ltd
  • The BioHub Birmingham
  • The Electrospinning Company
  • Theradex Europe
  • The Royal Veterinary College
  • Tillotts Pharma AG (Tillotts Services, Contract Manufacturing Division) (Switzerland)
  • Ventac Partners (Spain)
  • VHsquared Ltd
  • Wellcome Trust
  • West of England Academic Health Science Network
  • WilmerHale
  • World Courier
  • Ysios Capital (Spain)




BioTrinity 2014 highlights
1,014 delegates from 32 countries
624 companies
184 speakers
107 company showcase presentations
2,462 one-to-one meetings
130+ investor delegates from 12 countries
61 exhibitors
86 global pharma/medtech delegates
33 corporate venture delegates